[
    {
        "utterance": "Dr. Anna Moore: Sandin at the College of Human Medicine. Uh prior to joining MSU, which was about three years ago, uh my career all my career pretty much went at Massachusetts General Hospital and Harvard Medical School that I joined as postdoctoral fellow and by the time I left I was a professor at Harvard Medical School, professor in radiology. So, uh my personal interest in science is image guided therapy for metastatic cancers. ",
        "annotations": {
            "signal expertise": "Dr. Anna Moore explicitly states her qualifications and experience, indicating her expertise in a particular field."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Um, in the beginning of my career, I used uh iron oxide nanoparticles as contrast agents uh to detect tumors and now we're using them actually as uh carriers as vehicles to deliver therapies and as imaging reporters as well, that's why it's image guided therapy. ",
        "annotations": {
            "signal expertise": "Dr. Anna Moore is explicitly stating her own expertise and qualifications related to her research background."
        }
    },
    {
        "utterance": "Dr. Anna Moore: So that's it. Um, I mean, I can take tell you more, but I think we should try to keep it short. ",
        "annotations": {
            "express humor": "Dr. Moore attempts to make a joke about keeping her sharing short.",
            "process management": "Dr. Moore suggests managing the meeting flow by keeping her sharing short."
        }
    },
    {
        "utterance": "Dr. Anna Moore: So, um, I I'm just going to go the way I see people on the screen, so no or or no, I do have a list here. Okay, let's just go alphabetically. Benjamin. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by deciding to go through participants alphabetically and mentioning they have a list, indicating organization of group activities.",
            "encourage participation": "The speaker directly invites someone named Benjamin to contribute by mentioning his name."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Hi. Uh, I'm Ben Benjamin Bartel. I'm assistant professor just started this year at Arizona State University. I work on uh molecular tools for MRI. My goal is to uh non-invasively resolve and manipulate the neuroimmune system. So I do that with a combination of um uh just direct MRI methods uh through um just image analysis and I also build a host of molecular tools using directed evolution, signaling reporters, direct molecular sensors, etc. all for MRI and all in vivo. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states their position, work, and research goals, indicating their expertise in the field.",
            "develop idea": "The speaker elaborates on their research, detailing their work on molecular tools for MRI and their approach to non-invasively resolve and manipulate the neuroimmune system."
        }
    },
    {
        "utterance": "Dr. Anna Moore: We met yesterday, right? ",
        "annotations": {
            "ask question": "The utterance is a clear question seeking confirmation or information about a previous meeting."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah, I think we did. ",
        "annotations": {
            "Supportive response": "The speaker is expressing agreement with Dr. Anna Moore's statement about meeting previously."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, they screwed up a little bit the facilitators and the group, so I was supposed to be in the other group at the beginning. So, but that's fine. So it's all good to see faces that you've seen before. ",
        "annotations": {
            "process management": "The speaker is informally managing the group dynamic by referencing a previous mix-up.",
            "express humor": "The speaker makes a lighthearted comment about a previous situation."
        }
    },
    {
        "utterance": "Dr. Anna Moore: All right. Uh Molly. ",
        "annotations": {
            "process management": "Dr. Anna Moore is managing the meeting flow by moving on to the next person's introduction."
        }
    },
    {
        "utterance": "Molly Bright: Hi, I'm Molly Bright. I'm at Northwestern in Chicago. Uh, I also do in vivo work with MRI, but with humans. Um, I mostly look at quantifying aspects of the plumbing. So blood flow supplied to the tissue, how that blood flow is regulated or misregulated, um, aspects of oxygen delivery and metabolism. Uh, but I also like to think about how all of that vascular infrastructure supports or doesn't support healthy neural function. So, um, I do a lot of work now in in patients thinking about rehabilitation. So what can we do after something's happened to try to recover and repair both the neural and vascular systems. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her own expertise and qualifications related to the task by introducing herself and detailing her research background and interests."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. Wonderful. Dylan. ",
        "annotations": {
            "encourage participation": "Dr. Moore encourages Dylan to participate by calling out his name.",
            "process management": "Dr. Moore manages the flow of the meeting by moving on to the next person, Dylan."
        }
    },
    {
        "utterance": "Dylan Burnette: Hi, I'm Dylan Burnette. Um, I am an associate professor at Vanderbilt University. I just am just barely on the other side of tenure now. Uh although I still feel like I have like new people problems. Um, but I am a cell biologist by training and so I've been using light microscopes for about 20 years or so, a little bit more unfortunately. Um as I'm getting older. Uh to to study uh the cell skeleton. And so my my lab we kind of took that interest in in the cell skeleton to ask a very simple question. How does a heart grow on a single cell level? Meaning how does a single heart muscle cell physically get bigger? And that is one of the main drivers of our lab. Uh and we do attack that in multiple ways and it occurred to us a few years ago, actually about a year ago now that we could use the same technologies we're using to start mimicking what's happening inside of patients in in a in a uh basically a dish. And so we are now developing uh systems to mimic ischemia and reperfusion injury in our cardiac myos and that's allowed us to start doing screening and I have no idea what I'm doing and it's phenomenal. I have we're having a very good time. Uh and so we are kind of all over the place. We're we're looking at individual sarcomeres and we're looking to find some drugs. ",
        "annotations": {
            "signal expertise": "Dylan explicitly states his background and experience as a cell biologist.",
            "express humor": "Dylan makes a humorous comment about his situation."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. All right, sounds good. Morteza. ",
        "annotations": {
            "process management": "Dr. Anna Moore is managing the meeting flow by transitioning to the next person.",
            "encourage participation": "By calling out 'Morteza.', Dr. Anna Moore is inviting the next person to contribute."
        }
    },
    {
        "utterance": "Morteza Mahmoudi: Hi, my name is Morteza Mahmoudi and uh I'm an assistant professor at Michigan State University. My work is uh focused on nanomedicine and regenerative medicine and basically we use imaging technique to basically probe nanoparticles. if we use them for like therapeutic approaches like MRI approaches, if we use like magnetic based nanoparticles. Uh, but uh most importantly we try to understand what happens at the surface of nanoparticles. So for that purpose we combine cryo transmission electron microscopy and uh 3D constructed imaging model to basically see the 3D structure of the nanoparticles and how they interact with proteins and at the larger scale how they interact with different cell types and what are their uh trafficking inside the cells. ",
        "annotations": {
            "develop idea": "The speaker is expanding on his research area by explaining his work in nanomedicine and regenerative medicine."
        }
    },
    {
        "utterance": "Morteza Mahmoudi: Paris. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Paris Perdikaris: Hello everyone. So my name is Paris Perdicarris and I'm assistant professor at the Department of Mechanical Engineering at the University of Pennsylvania. Um, my background actually is in applied mathematics and my work is focused on developing machine learning methods and computational tools for modeling and simulation of physical and biological systems. I think most relevant to this meeting in some is some work I'm pursuing on physics based filtering of um uh in vivo MRI uh with a focus on 4D flow MRI and reconstructing blood flow and measurements in a way that the underlying physics is satisfied, so principles like mass and momentum conservation and then using those principles to infer auxiliary measurements that um cannot be measured by imaging such as blood pressure, uh shear stresses, um uh and so forth. So the idea there is really to understand the role of hemodynamics in determining organ function and uh you know, predicting biomarkers that are relevant to cardiovascular disease. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states his background and expertise in applied mathematics and his work on machine learning methods and computational tools.",
            "clarify goal": "The speaker mentions his work's relevance to the meeting, implying a goal of potentially collaborating or applying his work in a specific context."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Wonderful, Lisa. ",
        "annotations": {
            "Supportive Response": "The utterance 'Wonderful, Lisa.' expresses a positive sentiment towards Lisa, aligning with the definition of a supportive response."
        }
    },
    {
        "utterance": "Lisa Poulikakos: Hi everyone, I'm Lisa Poulikakos. I'm an assistant professor at UC San Diego. My research works on nanophotonics, so the study and manipulation of light at the nanoscale. Um, and some questions I'm really interested in is how can we scale down the complex manipulation of light. So a lot of these really sophisticated imaging techniques using state of the art nano optics can actually be realized on a single optical surface, which is then uh nano patterned in intricate ways and then can really be easily deployed in a variety of in vivo and ex vivo applications. Um and some questions that I find interesting um recently are how can we uh enhance polarized light matter interactions to learn more about the structural properties of molecules or tissues, for example. ",
        "annotations": {
            "signal expertise": "Lisa explicitly states her own expertise in nanophotonics and her research interests, signaling her qualifications and area of expertise."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay, thank you. Crystal. ",
        "annotations": {
            "acknowledge contribution": "Dr. Anna Moore is thanking someone for their introduction.",
            "encourage participation": "Dr. Anna Moore is inviting Crystal to contribute or introduce herself."
        }
    },
    {
        "utterance": "Crystal Rogers: Hi everyone. Uh my name is Crystal Rogers and I am an assistant professor at UC Davis. I am a developmental uh molecular and cell biologist and my research focuses on on understanding um the roles of transcription factors and cell cell adhesion molecules in regulating the process of the epithelial to transition. So I study neural crest cells um and those cells are really dynamic and they make a lot of different um adult tissues, but probably more relevant to this group, uh all of the molecular mechanisms that allow those cells to undergo EMT are then re uh reused by cancer cells to metastasize. And so what we are doing in my lab is really trying to get at the basal function of the proteins that allow these cells to undergo EMT and to migrate and differentiate and then um at least my postdoc is really interested in trying to define whether those functions um are conserved in disease states. And so we do a lot of fixed and live imaging of these cells to get at um how the collective migration works um and and the paths that these cells take and then um hopefully how that's affected by perturbations of these different proteins. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states their own expertise and qualifications related to the task, mentioning their position as an assistant professor at UC Davis and their research focus."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Very, very interesting. ",
        "annotations": {
            "supportive response": "The utterance 'Very, very interesting' expresses a positive evaluation of the contributions shared by other group members, fitting the definition of a supportive response."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Right in line with what we're doing too, so okay. Uh Mark. ",
        "annotations": {
            "Supportive Response": "Dr. Anna Moore is expressing agreement that Crystal Rogers' work is in line with what the group is doing.",
            "Acknowledge Contribution": "Dr. Anna Moore is also acknowledging Crystal Rogers' input."
        }
    },
    {
        "utterance": "mark sellmyer: that we can't do at this point. And another the other component is really around imaging gene and cell therapies and if we can image it and control it then perhaps we can get into that, you know, positive feedback loop of modulating something in the therapy and then seeing how that changes. So, um, thanks. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new idea about imaging gene and cell therapies.",
            "develop idea": "The speaker elaborates on the potential benefits and mechanisms of imaging gene and cell therapies."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. And uh I just don't want to mispronounce your name. Sixian, Sixian, is that the right way to say it? ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Sixian You: Uh, yeah, close enough. So my name is uh Sixian You. Yes. Uh, so I'm assistant professor in electrical engineering at MIT. I just started uh this March. Uh, I did my PhD in UIUC uh in label free microscopy. And then I did my uh postdoc in Berkeley in computational imaging. So my new lab uh the goal is to see how to use optics and algorithms to enable breakthroughs in biomedicine, especially the clinical adoption of microscopy in different uh biomedical situations like early cancer diagnosis, image guided therapies and neuroimaging. So I'm very interesting this session uh the reason I've never done anything like image guided therapies before, but uh I'm very curious how can I contribute? How can I use label free imaging, how can I use optics and algorithms to enable point of procedure diagnosis uh or point of procedure real time monitoring of the therapeutic process. Uh, what role would a resolution of cellular dynamics mean in the in the process of imaging guided therapies. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states his own expertise in electrical engineering, label-free microscopy, and computational imaging.",
            "ask question": "The speaker asks questions about how he can contribute, specifically about using label-free imaging and optics for point-of-procedure diagnosis and monitoring, and the role of cellular dynamics resolution in image-guided therapies.",
            "identify gap": "The speaker identifies a gap in his expertise by mentioning he has never done anything like image-guided therapies before."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. Thank you so much. And then there's other people who are not on my list. I don't know if you guys want to introduce yourself. Um. ",
        "annotations": {
            "ask question": "Dr. Anna Moore is asking if there are other people who want to introduce themselves.",
            "encourage participation": "Dr. Anna Moore is inviting others to introduce themselves, encouraging participation.",
            "process management": "The utterance manages the meeting process by ensuring everyone's introduction."
        }
    },
    {
        "utterance": "Arne Bakker (he/him) | CZI: So I'll just briefly say hi if that's okay just to you know who I am. I'm Arne Bakker, I'm at CZI, I'm the director of meetings and community um and so me and my team we host meetings like this about 15 to 20 times a year for the the the the scientists that CZI funds to really uh hope to encourage collaboration and sharing of knowledge. Um and I have a PhD in immunology and did my postdoc at Berkeley and my PhD at the Netherlands Cancer Institute in Amsterdam uh hence my interest in this topic. Uh but I'm mostly here to observe so I'm going to probably throw my camera off and and listen in but uh looking forward to hearing the conversation. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states his role at CZI, educational background, and experience in hosting meetings, which serves as a way to signal his expertise and qualifications.",
            "process management": "The speaker mentions his plan to observe and not actively participate by turning off his camera, which relates to managing his role or participation in the meeting process."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. And uh Sandra, do you want to say a couple of words? ",
        "annotations": {
            "encourage participation": "Dr. Anna Moore is inviting Sandra to contribute by asking if she wants to say a couple of words."
        }
    },
    {
        "utterance": "Sandra Laney - Walder Foundation: Yeah, just really quickly. I'm I'm a guest. I'm from the Walder Foundation based in the Chicago region um and I'm the senior program uh director for science innovation. So really just here as an observer looking forward to hearing the conversation. I also will probably shut my camera off and just participate as a butterfly on the wall. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her role and background as the senior program director for science innovation, signaling her expertise or qualifications."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. Um so um I guess the first thing we need to do is to select a person uh who's going to be recording uh all the great thoughts that hopefully come come out of this meeting. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by discussing the need to select a person to record the meeting's discussions.",
            "assign task": "The speaker is assigning the task of recording the meeting's discussions to one of the attendees."
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: I did it last time, so I'm not going to do it this time, but it was actually very fun. So somebody else should have that opportunity. You're just writing down sketches and then everybody likes you because you did the work. So. ",
        "annotations": {
            "encourage participation": "Benjamin invites others to take on the task of recording.",
            "express humor": "He makes a lighthearted comment about the task."
        }
    },
    {
        "utterance": "Dr. Anna Moore: That is very true Ben. So Ben did it the last time yesterday and he did an an amazing job. ",
        "annotations": {
            "acknowledge contribution": "The speaker is verbally recognizing Benjamin Bartelle's previous input.",
            "supportive response": "The speaker is expressing a positive evaluation of Benjamin Bartelle's contribution."
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: Yeah. ",
        "annotations": {
            "code name": "Supportive response",
            "explanation": "The speaker is expressing agreement or validation, even if minimally, with a previous statement."
        }
    },
    {
        "utterance": "Dr. Anna Moore: And uh as uh Andrew pointed out, you don't need to fill up that slide uh right away because I guess I guess there's some I don't know, interference or something. My internet is not working very great either. So uh you can just write it down somewhere and then transfer it on the slide. So Ben, do you do you want to just basically give people like a couple of ideas how to do that? So they because they they will look a little bit scared. ",
        "annotations": {
            "process management": "Dr. Anna Moore is managing the meeting flow by discussing how to record ideas and handle technical issues.",
            "encourage participation": "Dr. Anna Moore involves Ben in the discussion by asking him to provide guidance on recording ideas."
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: Sure. We're um so you know, we all had a conversation yesterday that when people would make a point, they come in and say like, I don't know, we could one thing was we collect more data than we use these days. And so I just wrote that down. Somebody else said, you know, I'm involved in really these large scale projects and we try to collect data for other people. Like, okay, well, put those things together and I just started cluster together the the main points people were making. And they ended up being in about three general categories. And so at the end, I was like, hey everybody, things kind of went into these three categories. That's great. ",
        "annotations": {
            "summarize conversation": "The speaker is summarizing the conversation from the previous day, highlighting key points made by others.",
            "develop idea": "The speaker is developing ideas by organizing and synthesizing information from previous discussions into categories."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Uh we we we sure did. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: It's great to be appreciated. I'm just trying to sell it. ",
        "annotations": {
            "acknowledge contribution": "Benjamin is acknowledging Dr. Anna Moore's appreciation for his work.",
            "supportive response": "His response is positive and appreciative.",
            "express humor": "His response has a humorous tone."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Thank you, appreciate that too. All right, so any volunteers? ",
        "annotations": {
            "acknowledge contribution": "Dr. Moore verbally recognizes another group member's input.",
            "encourage participation": "Dr. Moore invites others to contribute or participate in a specific activity."
        }
    },
    {
        "utterance": "Sixian You: That is what. I can do it. I'm a newbie in image guided therapies anyway, so I I'm here to absorb and learn. ",
        "annotations": {
            "code name": "Process management",
            "explanation": "The speaker is volunteering for a task, which relates to managing their participation in the meeting."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. Sixian, thank you so much. That's uh great. So it's actually up to you. You can write, you know, write in the slide if you want. It's up to you or on the, you know, piece of paper on or on the computer screen and then. ",
        "annotations": {
            "process management": "The speaker is directing the flow of work or tasks within the meeting, specifically regarding note-taking or recording."
        }
    },
    {
        "utterance": "Sixian You: Uh, yes. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Dr. Anna Moore: No, no, no, it's slide 42. ",
        "annotations": {
            "process management": "Dr. Anna Moore is managing the meeting flow by specifying the slide number she is referring to."
        }
    },
    {
        "utterance": "Sixian You: 42. Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance in a substantial manner"
        }
    },
    {
        "utterance": "Dr. Anna Moore: Uh, it's the recovery slide or is the original slide? ",
        "annotations": {
            "ask question": "Dr. Anna Moore is requesting clarification on which slide is being referred to, indicating she is seeking information."
        }
    },
    {
        "utterance": "Molly Bright, Northwestern: Whichever one is for our room. It doesn't matter what number slide it is. If it's the one for 2.3. ",
        "annotations": {
            "supportive response": "Molly is being supportive and flexible about the slide number.",
            "process management": "Molly is helping manage the process of selecting a slide for their session."
        }
    },
    {
        "utterance": "Lisa Poulikakos, UCSD: So we're saying there's versions of the document and we should use the one that doesn't say recovery somehow just so if I understood correctly. ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on which version of the document to use.",
            "process management": "The speaker is also managing the meeting process by clarifying the document version to be used."
        }
    },
    {
        "utterance": "Molly Bright, Northwestern: Got it. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Sixian You: That makes sense. Okay. ",
        "annotations": {
            "supportive response": "The utterance expresses agreement or validation with a previous statement, indicating a supportive response."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, I have a slide that doesn't say recovery. Well, okay. ",
        "annotations": {
            "Supportive response": "Dr. Anna Moore is acknowledging and agreeing with the previous discussion.",
            "Process management": "Dr. Anna Moore is facilitating the meeting by confirming the use of a particular slide.",
            "Confirm decision": "Dr. Anna Moore is confirming the use of a particular slide."
        }
    },
    {
        "utterance": "Sixian You: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it is a minimal response that does not explicitly fit into any of the provided categories."
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: already entered her name. ",
        "annotations": {
            "acknowledge contribution": "Benjamin Bartelle ASU is acknowledging that he has entered someone's name, likely in response to a request or as a note of action taken."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, you can just do that. Okay, great, excellent. ",
        "annotations": {
            "supportive response": "The speaker, Dr. Anna Moore, expresses agreement and approval with a previous suggestion, indicating a positive and encouraging response."
        }
    },
    {
        "utterance": "Dr. Anna Moore: All right, so here we go. Um from models to humans. Um so basically the question is we have uh a lot of uh drugs in the pipeline in in uh petri dishes in the labs uh that were beautifully uh when you seed the cells, you know, and then you sprinkle the drug, cells dead, all good. Uh, totally different issues when you start injecting something in the body, whether it's a mouse, a rat or or human. Well, you can't inject in the human before you inject in the mouse and the rat but anyway, so the big issue is how do you how do you get something somewhere where it needs to go? What are the biological barriers that needs to be overcome? Uh, and the biggest question, I guess, you all know that it takes about 10 years to get something from the bench to to being somewhat approved. Not even fully approved, but somewhat approved. 10 years, uh, tens of millions, sometimes hundred millions of dollars. Just just something has to something has to be done about that. So, um, so we're here to to solve this problem today. ",
        "annotations": {
            "propose new idea": "The speaker introduces a direction to solve the problem of translating drugs from models to humans.",
            "clarify goal": "The speaker defines the objective of the meeting, which is to address the challenge of moving drugs from bench to approval."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yes. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Crystal Rogers (UC Davis): So as a mechanistic scientist, I just want to to bring up this, you know, start at the base level basically, that the issue or one of the big issues that we have with this is that the con. ",
        "annotations": {
            "develop idea": "Crystal is expanding on the discussion by offering her perspective as a mechanistic scientist and suggesting to start at a basic level to address the issues."
        }
    },
    {
        "utterance": "Crystal Rogers (UC Davis): of these processes or or you know, pathways, they're not even conserved between people, much less species. And so we have a really uh significant issue if we focus on one model organism and there's no confirmation of of pathways, molecular pathways for treatments. And so as you mentioned, something can be targeted in the mouse and never works in the human and doing research with model organisms, even closely related ones, I can tell you that even within the same order, there's no guarantee that these species have um kind of the same there's not the mechanistic processes aren't the same. So I think we need a lot more basic level research to really define what the conserved pathways that drive these processes of say EMT, cell migration, metastasis are, um before we can jump to treating humans and and we have to have both of those at the same time in my opinion. ",
        "annotations": {
            "develop idea": "Crystal expands on the challenges of translating research findings from model organisms to humans, emphasizing the need for understanding conserved pathways.",
            "identify gap": "Crystal points out the significant gap in current research - the lack of understanding of conserved molecular pathways across species.",
            "signal expertise": "Crystal shares her perspective based on her expertise in molecular and cell biology, particularly in EMT and cell migration."
        }
    },
    {
        "utterance": "Lisa Poulikakos (UCSD): Could I ask a follow up on on Crystal's comment? So I come from the optics and physics side so I'm just learning recently about the biological model making and so on. So how much do some of these relatively recent um 3D physiologically relevant cell culture models help? So so making basically um so so from you know, my reading and talking to some collaborators it seems like people are getting better at making in vitro models of of the human also for drug testing for example. So does that help maybe avoid some animal models or is that completely often brings along a whole other set of challenges? What's kind of the latest um state of the art there? ",
        "annotations": {
            "ask question": "The speaker is requesting information about the effectiveness and challenges of 3D physiologically relevant cell culture models.",
            "develop idea": "The speaker is building upon Crystal's previous comment about the limitations of model organisms."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Are you talking like you know, like spheroid cultures and stuff? ",
        "annotations": {
            "ask question": "The speaker is requesting clarification on a previous statement, specifically asking if spheroid cultures are what Lisa Poulikakos was referring to."
        }
    },
    {
        "utterance": "Lisa Poulikakos (UCSD): Mainly cell cultures that can reproduce for example also the extracellular environment. So so that are really physiologically relevant but in vitro. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on the concept of cell cultures that can reproduce the extracellular environment, highlighting their physiological relevance but also noting they are in vitro."
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: It feels very promising, but my personal experiment experience uh recently collaborating with somebody doing a 3D organoid model. Um we got all kinds of interesting data in addition that I went to go validate with some metabolic imaging, just nothing alike. Not even slightly. And so then we just did all the experiments over again and it told a completely different story. It turned out that, you know, sitting in millimolar glucose, which is what you have to do for the cells to survive, completely wrecked their metabolism in terms of you know, what we're looking for. So it is really easy to get to be misled by those tools. I'm not saying they're bad, but it's very easy to get misled because then you think they're real, but something that's required for the culture conditions um ruins everything. And for someone who works in neuroimmunity, like the microglia that I focus on, they know when they're in culture. They know when they're being looked at and they change their their gene transcription. So those things have been have been very frustrating for for my personal kind of work. Now, they may work in other systems, but they they've never worked for me. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea of using 3D organoid models by sharing his personal experience with them.",
            "critical response": "The speaker is providing a critical perspective on 3D organoid models based on his research experience.",
            "offer feedback": "The speaker is offering feedback on the use of 3D organoid models, highlighting potential pitfalls and limitations."
        }
    },
    {
        "utterance": "Sixian You | MIT: I think there are some positive examples for uh breast cancer. So there is a research group in Wisconsin Medicine where they uh have these organoids from patients and they culture it and then they use therapy to uh you know, treat it and then using optical imaging technologies, they are able to see if they decrease or increase. Uh I have not been following up how well that really translates to the patient's recovery because of course that takes long time to track. Uh but maybe the sensitivity. I know neurons are a beast. They are different in every different environment. So maybe some models are more robust in different um scenarios and that's the thing we could take advantage of. ",
        "annotations": {
            "develop idea": "The speaker is expanding on an existing idea by providing a concrete example of research in breast cancer using organoids and optical imaging technologies.",
            "supportive response": "The speaker is providing information that supports or elaborates on a previous discussion by sharing a relevant example."
        }
    },
    {
        "utterance": "Dylan Burnette: Yes, I would I would get I would agree with that. Not all organoids are the same. Uh there are some organoids that are much more robust and in vivo like such as the gut organoids are actually making real crips to feed the villi that have the the sites on them. And also the Which I'm referring to gut organoids as well what we're doing. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement with a previous statement.",
            "develop idea": "The speaker is expanding on the idea by providing specific examples of organoids and their capabilities."
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: Which I'm referring to gut organoids as well what we're doing. ",
        "annotations": {
            "develop idea": "The speaker is expanding on a previous idea or discussion about organoids, specifically mentioning gut organoids and relating it to their work."
        }
    },
    {
        "utterance": "Dylan Burnette: But that was metabolism. Yeah yeah yeah don't don't don't expect them to actually have the right metabolism. That's just that's a big ask. It's surviving and making similar cell types is what we're looking for here. Um that's why I think people we should we should lower our standard a little bit because to expect a something in a dish to be an in vivo environment is never going to happen. In vivo like we can probably get there. In vivo you got to go into an animal for that. ",
        "annotations": {
            "develop idea": "The speaker is expanding on previous discussions about organoids and their capabilities, particularly in relation to metabolism and in vivo environments.",
            "critical response": "The speaker is offering a critical perspective on the capabilities of organoids.",
            "offer feedback": "The speaker is providing feedback on the use of organoids and the expectations surrounding their development."
        }
    },
    {
        "utterance": "Crystal Rogers (UC Davis): I was going to mention the same paper. Although somebody commented that the mechanism of formation was different in vivo versus in the organoid, but that the function was similar. So I do think there are limitations. ",
        "annotations": {
            "develop idea": "Crystal is expanding on an existing idea by discussing the functional similarities and mechanistic differences between organoids and in vivo environments.",
            "critical response": "Crystal is pointing out limitations and differences in mechanisms between in vivo and organoid environments.",
            "supportive response": "Crystal is showing agreement or validation of previous concerns about limitations."
        }
    },
    {
        "utterance": "Crystal Rogers (UC Davis): But I think multi-disciplinary studies where you have people in vivo and you have organoids and then you are able to, I mean we can't study people, but you can do um patient specific therapeutics, right? So pulling cells or um or tumors out of patients to try to determine in their physiology if they can respond to these things. You kind of have to have all three because with without them you're you're running blind in some areas. ",
        "annotations": {
            "develop idea": "Crystal is expanding on previous ideas about the limitations and potential of different research methods by suggesting a multi-disciplinary approach.",
            "identify gap": "Crystal recognizes a gap in knowledge or effectiveness when using a single research approach, suggesting that without multiple approaches, researchers would be 'running blind in some areas'.",
            "supportive response": "Her comment supports the idea that a combination of research methods is necessary for comprehensive understanding and effective therapeutics."
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: I think some of us are you can't study people though, right? Uh Molly, you study people, but what you get is not mechanistic per se. It's like a convolution of the mechanisms. And so there's got to be some I I I wish there is some translation between the mechanisms and the convolute the complex outputs of those mechanisms. And a lot of times that's things like blood flow because that's something you can see or biomarkers that are accessible, structural changes, um liquid biopsies, things like that that give you hints as to what the mechanism might be. But um so far uh those things have not been enough to give you a a strong inference of the mechanisms that are so have been so painstakingly acquired in in model systems. ",
        "annotations": {
            "develop idea": "The speaker is expanding on previous discussions about research methods and their limitations.",
            "ask question": "The speaker is implicitly asking for a way to translate mechanisms from model systems to human studies.",
            "critical response": "The speaker is providing a critical perspective on the current state of research, highlighting the gap between model systems and human studies."
        }
    },
    {
        "utterance": "Dylan Burnette: My lab's cheating a little bit. We are not looking at small molecules, we're looking at drugs. So we're trying to repurpose FDA approved drugs because I don't really develop drugs. Uh so that's that that's how we're skirting around this issue of like you develop a small molecule that's very effective in in vitro, you go into a patient doesn't it doesn't partition correctly in the body. What the heck's no, after 10 years of work, that's annoying. So we are we are we're cheating a little bit by uh just focusing right now on repurposing FDA approved drugs that have a huge literature. So the mechanism has been delved into in vitro, in animal models and in humans as much as we can. So um there's a way around that. Now, not every problem can, you know, uh we can't pull an FDA approved drug off the shelf for every single problem. That's not going to be feasible, but there's a good handful I think we can. ",
        "annotations": {
            "develop idea": "Dylan is elaborating on his lab's approach to drug development, specifically how they are repurposing FDA-approved drugs.",
            "express humor": "Dylan uses the phrase 'cheating a little bit' to lighten the mood when discussing his lab's approach.",
            "signal expertise": "By discussing their approach and experience, Dylan is signaling his and his lab's expertise in the area."
        }
    },
    {
        "utterance": "Dr. Anna Moore: So, so one of the issues is uh like I said before, is delivery and imaging that delivery. And I know that there's a maybe handful of drugs that allow for that. In fact, if I start scratching my head and trying to name one, I probably wouldn't be able to. Uh there's something on the pet side that's available, I think, but nowhere else. Do you think that this is a an important issue to be able to to see what you're delivering and where? ",
        "annotations": {
            "identify gap": "The speaker highlights the difficulty in delivering drugs and imaging that delivery, pointing out a gap in current capabilities.",
            "ask question": "The speaker requests input from others on the importance of being able to see what is being delivered and where.",
            "encourage participation": "The speaker invites others to contribute their thoughts on the issue."
        }
    },
    {
        "utterance": "mark sellmyer: I I can I can try to uh comment on that. I mean, I think the oldest uh sort of theranostic, maybe radioactive iodine for thyroid cancer. Because there you're getting a beta emission, which is killing the actual tumor and then or the thyroid in general and then you're also getting the uh gamma emission that you can detect with the camera. And so, um in my group, um you know, we've been interested in in uh well there's quite a there's quite a lot of efforts out there that are along these lines, especially the nanoparticle community, which can label, you know, things with both therapeutics and diagnostics. My group is stuck on the concept of uh reporter genes. And because GFP's been so critical to, you know, microscopy and biomedical applications and and study, you know, if we could develop good reporter genes for in vivo and human applications, that seems critically important to look at like living drug therapies. So cells that are being regenerative medicine for your cardiac myocytes or um you know, uh car T cells are a modern example, um virally delivered vectors another another example. And so, you know, to me on that front, if you can if you can image the delivery of these types of therapeutics that have different PK because they are tend to um sense and respond to pathology, that makes it a totally different problem than just what the admin characteristics are of a of uh chemotherapy or a biologic. So I think I think the idea is is ",
        "annotations": {
            "signal expertise": "The speaker signals their expertise in biomedical applications and genetics by discussing specific concepts and their implications."
        }
    },
    {
        "utterance": "mark sellmyer: is really important and how do we develop things that are able to sense drug delivery. There's also the idea um from pet because I do pet on some of my day job that you can radio label the drug itself or something that's going to um show you whether or not you're inhibiting with therapeutic doses. So example of this is the estrogen receptor um and people have made drugs like full vestrant which are estrogen receptor degrader. So that drug binds to the estrogen receptor and it's got a hydrophobic group on it that targets the whole receptor to be degraded. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states their experience with PET in their day job.",
            "offer feedback": "The speaker provides a specific example of a drug and its mechanism to illustrate their point.",
            "develop idea": "The speaker elaborates on the concept of sensing drug delivery by providing a specific example."
        }
    },
    {
        "utterance": "mark sellmyer: Now if you make a estrogen receptor estradiol 4 and 18 probe, then you can use that to monitor the success of your estrogen receptor degrader in people. And so um people have have done this and it's becoming part of the standard of of drug development is try to try to develop companion diagnostic agents that are going to let you look at drug delivery and I'll stop. ",
        "annotations": {
            "develop idea": "The speaker is expanding on a concept related to drug development and diagnostic agents, building upon existing knowledge.",
            "offer feedback": "The speaker is providing a specific example and suggestion for how to monitor drug delivery, implying a way to improve or approach the issue of drug development."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, not not only drug delivery but also the the target engagement and dis disappearance of the target if that's the if that's the goal. ",
        "annotations": {
            "Develop idea": "The speaker is expanding on previous ideas about drug delivery and its challenges, adding the aspect of target engagement.",
            "Clarify goal": "The speaker is clarifying what is important for their research goals, specifically mentioning drug delivery, target engagement, and disappearance of the target."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Um so so the word nano has been said several times. So um I I would like you guys to uh to give some thoughts about the future of nanotechnology in that regard. Um those of you who work in that area maybe want to speak a little bit. ",
        "annotations": {
            "encourage participation": "The speaker invites others to contribute their thoughts and expertise, specifically asking those who work in the area of nanotechnology to speak up."
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: Yeah, before can I comment on that? So before going to nanotechnology, I just wanted to add one more thing and it's that like the problems of the in vitro make sense from different angles when you look at it. I mean from the like the biological point of view, it makes perfect sense that they don't basically recapitulate what happens in vivo. ",
        "annotations": {
            "develop idea": "Morteza is expanding on previous ideas discussed about the limitations and challenges of in vitro models compared to in vivo models.",
            "offer feedback": "Morteza is providing his perspective on in vitro and in vivo models, which serves as feedback to the ongoing discussion."
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: But like from the physical point of view, it would be another story like different organs have different stiffness. They have like different properties and all of those things needs also to be considered in the in vitro setting. Like with the advances in the 3D bioprinting and like making like um uh pattern substrates that can basically provide opportunity for cells to basically make a 3D structures rather than like the flat surface uh 2D structured, all of those can be of a great help for getting more meaningful and robust in vitro data. So I think for that purpose maybe a group of scientists that have different looks into the same problem needs to collaborate to each other to basically make a perfect in vitro like setting that can be more close to the in vivo part. ",
        "annotations": {
            "propose new idea": "The speaker introduces new ideas on considering physical properties of organs in in vitro settings and potential solutions like 3D bioprinting.",
            "develop idea": "The speaker elaborates on the concept and its implications for in vitro settings.",
            "encourage participation": "The speaker encourages collaboration among scientists from different backgrounds."
        }
    },
    {
        "utterance": "mark sellmyer: I'll just say on that that frame too like it's not only to just do the study if you could or study basic biology, if you can start making better 3D culture systems and start to grow organs, there's also huge biomedical applications and treatments that can come out of it. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea of using 3D culture systems for biomedical applications, suggesting this could lead to significant advancements.",
            "supportive response": "The speaker is expressing a positive view on advancing 3D culture systems for biomedical applications.",
            "offer feedback": "The speaker provides a perspective on the potential benefits of advancing these technologies."
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: Yeah, exactly. These are basically the concept of the lab on a chip which basically again it's a kind of multidisciplinary thing. And for the nanotechnology, I mean, we are working in the field of nanomedicine for a couple of years and like one of the main problems that we have for delivery and also for like using them as a contrast agent is their interactions with biological systems. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the concept of 'lab on a chip' and its implications for nanotechnology and nanomedicine.",
            "identify gap": "The speaker highlights a main problem in nanomedicine, which is the interaction of nanoparticles with biological systems."
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: So what happens is that what we makes in like laboratories are totally different from what we see like when they interact with the plasma proteins or any type of biological fluids. So what happens is that different types of biomolecules comes to the surface of nanoparticles and interact with them and basically form a corona around the surface of nanoparticles. So based on the type of the proteins, amount of the proteins, conformational changes of the proteins, basically we have totally different fate for the nanoparticles. So it can affect imaging, it can affect targeting, it can affect safety of the nanoparticles and those things basically needs to be considered in the imaging like procedures because you can imagine when you have additional layer at the surface of like nanoparticles, if you use that nanoparticles as a carrier, so what happens is that they can affect drug release. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the concept of nanoparticle interactions with biological systems, specifically the formation of a protein corona and its implications.",
            "signal expertise": "The speaker is explicitly stating their knowledge and background in the field of nanomedicine and nanoparticle interactions with biological systems."
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: Or if you have like a fluorophore or something like that and what happens is that we may have like some unwanted interactions with those like labeling species that can affect the like the imaging capacity. So from a nanotechnology perspective, I would say we need more information about like the protein corona and how it can affect the safety and biological like fate of nanoparticles. ",
        "annotations": {
            "identify gap": "The speaker explicitly mentions a need for more information about the protein corona and its effects on nanoparticles.",
            "develop idea": "The speaker is elaborating on the challenges of using nanotechnology, specifically about interactions with biological systems."
        }
    },
    {
        "utterance": "Lisa Poulikakos, UCSD: So maybe also to follow up on Morteza's point um so in my research I focus a little bit more on using nanotechnology to manipulate the light. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the existing discussion about nanotechnology by sharing her research focus on using nanotechnology to manipulate light."
        }
    },
    {
        "utterance": "Lisa Poulikakos, UCSD: So I think there is there's the whole field of you know, having nanoparticles in the body and and Morteza really nicely outlined also several of the challenges that come with that. Um and I think some of uh you know, what I think is kind of a new direction in using nanotechnology is actually um not necessarily having it interact directly in the body but having it manipulate the light with which you illuminate uh the part the biological species you want to see and actually then using light itself as a marker. ",
        "annotations": {
            "propose new idea": "Lisa suggests a new direction for using nanotechnology to manipulate light as a marker for studying biological species.",
            "develop idea": "Lisa expands on Morteza's discussion about the challenges of nanoparticles and develops the idea towards a new application."
        }
    },
    {
        "utterance": "Lisa Poulikakos, UCSD: Um and some of the things I I'd also love to get people's perspective on there is um for example also as Morteza was saying, there are new ways where you can better um model the tissue in three dimensions and actually get effects such as the extracellular matrix um and and for instance in breast cancer metastasis, the extracellular matrix actually plays a really critical role. So um I'm curious to know how do people image that today because I think using sophisticated nano optics it would be potentially possible to monitor that. ",
        "annotations": {
            "ask question": "The speaker asks for information on how people currently image the extracellular matrix.",
            "encourage participation": "The speaker invites others to share their perspectives on using nano optics for imaging biological systems."
        }
    },
    {
        "utterance": "mark sellmyer: It's a great question how to image the matrix. There aren't great tools as I understand. Maybe someone else knows. I think there's some MR techniques and someone MR might be Molly can jump in and correct me but I think there are ways to look at like higher how hyaluronic acid or you know, things that are around but I I don't know too much that's um specific to ECM like imaging collagen. I mean, I guess the other other techniques that come to mind are like MR elastography that's like Yeah and and ultrasound sort of stiffness measurements. ",
        "annotations": {
            "ask question": "The speaker requests information on how to image the matrix.",
            "acknowledge contribution": "The speaker acknowledges Molly's potential expertise in MR techniques.",
            "offer feedback": "The speaker provides suggestions for techniques to image the ECM, including MR techniques, MR elastography, and ultrasound."
        }
    },
    {
        "utterance": "mark sellmyer: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "mark sellmyer: Just some extent you oh go ahead. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Dr. Anna Moore: Talk to me. ",
        "annotations": {
            "ask question": "The speaker is implicitly requesting information or discussion.",
            "encourage participation": "The speaker is inviting others to contribute to the conversation."
        }
    },
    {
        "utterance": "Dr. Anna Moore: I was just going to say that, you know, perfusion and diffusion imaging goes this it's in the same category. ",
        "annotations": {
            "summarize conversation": "The speaker is summarizing or relating different imaging techniques by putting them into the same category."
        }
    },
    {
        "utterance": "Benjamin Bartelle, ASU: Well, to some extent you can use MRscopy. Um people have picked up hyaluronic acid that way, but it's only for things that are highly um highly present there. So what is the signaling space of the ECM, what kind of cytokines have been decorating the ECM, all that stuff is kind of beyond the reach of clinical imaging without a biopsy. ",
        "annotations": {
            "develop idea": "The speaker is expanding on previous discussions about imaging techniques and their limitations.",
            "identify gap": "The speaker highlights a gap in the capability of clinical imaging to detect certain components of the ECM without a biopsy.",
            "critical response": "The speaker is pointing out the limitations of current clinical imaging techniques."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, lactate. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah. ",
        "annotations": {
            "None": "The utterance is a minimal response that acknowledges a previous statement without adding new content."
        }
    },
    {
        "utterance": "mark sellmyer: Yeah, I mean, I I think like as a big field a big wide open blue ocean of research really is the extracellular space because we know so much about cell biology, but like we don't really even know what happens to proteins very well once they get in the extracellular space, especially in the animal. So uh and it's very it's a challenging field, right? Because it's hard to um model that in in as we got this comes full circle back to the culture conditions question. ",
        "annotations": {
            "identify gap": "The speaker identifies a gap in knowledge regarding the behavior of proteins in the extracellular space.",
            "develop idea": "The speaker expands on the challenges and complexities of researching the extracellular space.",
            "offer feedback": "The speaker provides perspective on the challenges of researching the extracellular space, implying areas where more knowledge is needed."
        }
    },
    {
        "utterance": "mark sellmyer: Tough. ",
        "annotations": {
            "critical response": "The speaker expresses a challenge or difficulty with the topic being discussed, implying a critical view of the complexity of the problem.",
            "identify gap": "The speaker's comment also implies an identification of a gap in current capabilities or understanding, by acknowledging that the problem is tough."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay, so I I think that uh at the end of this um at the end of the session we will need to produce some ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by mentioning the need to produce something by the end of the session.",
            "clarify goal": "The utterance implies a goal of producing something, though not clearly defined."
        }
    },
    {
        "utterance": "Dr. Anna Moore: ideas and some hard pressing questions, uh what is on the way from translating things um from models to humans. ",
        "annotations": {
            "clarify goal": "The speaker is discussing the objective of translating findings from models to humans, which involves defining and clarifying goals."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Um in in all those various areas, not just, you know, drug delivery but just imaging. Even translating imaging agents uh that also requires some jumping through the loops. ",
        "annotations": {
            "summarize conversation": "The speaker is summarizing previous discussions, referring to various areas such as drug delivery and imaging, and highlighting the challenges in translating findings."
        }
    },
    {
        "utterance": "Sixian You | MIT: Yeah, I'm really curious to know like um why why it takes 10 years, this is a very naive question. Why it takes 10 years to develop drugs and uh why it takes uh thousands of millions. ",
        "annotations": {
            "ask question": "The speaker is requesting information about why it takes 10 years and thousands of millions of dollars to develop drugs."
        }
    },
    {
        "utterance": "mark sellmyer: I guess how much clinicians get paid, it's uh, you know. ",
        "annotations": {
            "express humor": "The utterance makes a humorous comment suggesting that clinicians' pay might be a factor in the high cost and lengthy process of drug development."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Okay. Sorry guys, it's a big part of it. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement or acknowledgment, implying that financial aspects are a significant part of the issue with drug development."
        }
    },
    {
        "utterance": "mark sellmyer: As the as the clinician on the call, I can't defend anything here, but I guess the um, the the thing that strikes me is is the sheer just amount of research that needs to go in to validate safety and the amount of time that that takes and effort. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states their role as a clinician.",
            "supportive response": "The speaker is providing an explanatory response, though not directly agreeing or validating, it's about sharing their perspective."
        }
    },
    {
        "utterance": "mark sellmyer: And then doing, you know, to get something to as an imaging probe, it's actually frankly somewhat markedly easier to get into the clinic than it is for a therapeutic where imaging probes generally are benign, right? They're not going to kill you, a radio tracer is low, MR contrast agents may be harder. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the differences between imaging probes and therapeutics in terms of ease of getting into the clinic, highlighting their relative safety and the implications for clinical development.",
            "clarify goal": "The speaker is also discussing and clarifying the goals and challenges associated with developing and approving imaging probes versus therapeutics."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Somehow we've convinced people of this. Yeah, it's amazing. But yeah. ",
        "annotations": {
            "supportive response": "The utterance expresses agreement and validation for a collective achievement or agreement reached by people."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, yeah, because, you know, radio tracer, you inject them in such a small, small quantity that, you know, it's. ",
        "annotations": {
            "develop idea": "The speaker is expanding on a previous point by providing an explanatory statement about radio tracers."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Oh yeah, I'm talking about Gadolinium. That's just. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges a previous mention of Gadolinium, showing they are engaging with and building upon earlier discussions."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, Gadolinium. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Benjamin Bartelle: It's some reason it's okay to put in millimolar amounts of Gadolinium into a person. ",
        "annotations": {
            "Critical Response": "The speaker is questioning the practice of using millimolar amounts of Gadolinium, implying a negative evaluation of its safety or efficacy."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, there's a warning on the label. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Benjamin Bartelle: The debate the debate rages, yeah. ",
        "annotations": {
            "Express humor": "The speaker is making a light remark about the ongoing debate, indicating a humorous tone."
        }
    },
    {
        "utterance": "mark sellmyer: But but I think, you know, the therapeutic index for a therapy is a huge deal, right? If you you don't want to be causing toxicity and in the realm of do no harm, right? It it just takes us. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the concept of therapeutic index and its significance in therapy.",
            "supportive response": "The speaker is expressing agreement or validation with the context of discussion, emphasizing a principle (do no harm) that aligns with the group's objectives."
        }
    },
    {
        "utterance": "mark sellmyer: So so Sian, I I I don't know how to answer the question other than to say like as imagers, we actually are in a better position of um, getting things translated. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the challenges of drug development and the role of imaging.",
            "offer feedback": "The speaker provides perspective on the role of imagers in drug development.",
            "signal expertise": "The speaker is stating his perspective as an imager in the field."
        }
    },
    {
        "utterance": "mark sellmyer: So like, you know, this was there's image guided therapies being here. People have developed fluorescent probes to thing like folate receptor or looking at um ICG for various lung cancers. So people have taken, you know, molecular imaging approaches and put those into patients without a huge, you know, long, long time to get those um, we're talking years rather than 10 years maybe to do this. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the concept of molecular imaging approaches and their applications in patients.",
            "signal expertise": "The speaker is demonstrating knowledge in the field of molecular imaging and its applications.",
            "supportive response": "The speaker is providing information that supports the feasibility of translating molecular imaging approaches into clinical practice."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, but you know, answering your question uh Sian is um, you know, just just look at the catalog from uh Charles River, you know, how much you pay for a transgenic animal. You know, it's like 250 bucks for one mouse. ",
        "annotations": {
            "develop idea": "The speaker is expanding on a previous idea related to drug development costs and complexities by providing a specific example."
        }
    },
    {
        "utterance": "Benjamin Bartelle: That's a deal. ",
        "annotations": {
            "Supportive response": "The speaker is expressing agreement or validation for the previous statement about the cost of a transgenic mouse.",
            "Express humor": "The speaker's comment can be interpreted as humorous, playfully responding to the high cost of a transgenic mouse."
        }
    },
    {
        "utterance": "Benjamin Bartelle: We transgenic GQ animals, 400 bucks anyway. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Dr. Anna Moore: I know. I'm with you, I'm with you. I know. And yeah, those are even higher. And then you need n equals more than three, right? To do anything, you know, anything meaningful. And then um, all the antibodies and everything, and then once you're done with the with the with the pre-clinical studies in your lab. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on previous discussions about the challenges of pre-clinical studies.",
            "identify gap": "The speaker mentions the need for a higher number of samples for meaningful results.",
            "supportive response": "The speaker is expressing agreement and validation with previous statements."
        }
    },
    {
        "utterance": "Dr. Anna Moore: You go to CROs, uh, which are contract research organizations to do tox, to do PKPD, that's all required by FDA. And I hate to show you the bills from those companies because I went through that with my uh, with the compound that we're developed. You just, you know, basically wondering, you know, how can you possibly pay for all that? So, and then, uh, the companies that, you know, they invest money in this and then they want to recover those money and then we're wondering why the drugs are so expensive because if so much money you want to recover it somehow, right? ",
        "annotations": {
            "Develop idea": "The speaker is elaborating on the process of drug development and the associated costs.",
            "Identify gap": "The speaker highlights the issue of high drug costs and the lengthy process of drug development.",
            "Critical response": "The speaker is critiquing the high costs and the system of drug development indirectly."
        }
    },
    {
        "utterance": "Benjamin Bartelle: There's a ray of light. ",
        "annotations": {
            "supportive response": "The speaker is expressing a positive outlook or optimism regarding the challenges discussed in the conversation."
        }
    },
    {
        "utterance": "Benjamin Bartelle: And that this builds on something Dylan brought up earlier is um, you were saying you're using clinically approved drugs in your your studies and that sort of gives you a shortcut, right? With the 90% of investment in new medicines is in biologic drugs. Most of these are antibody based drugs, right? And they're going after specific targets. ",
        "annotations": {
            "develop idea": "The speaker is expanding on an existing idea by discussing the use of clinically approved drugs in studies.",
            "acknowledge contribution": "The speaker acknowledges Dylan's previous point.",
            "supportive response": "The speaker is expressing agreement and building on the previous idea."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Like I made an antibody against this target, antibody against that target, I've proved that it's focal enough where it doesn't cause the worst side effects. Because of the modularity of nanotechnology and biological systems, the what everyone is doing right now, at least in the synthetic biology space, is they're starting with that. like we know this biologic drug hits this target safely. And so now we're going to build a car T cell therapy around that biologic drug. ",
        "annotations": {
            "develop idea": "Benjamin is expanding on how antibodies are used and applied in synthetic biology, specifically in building car T cell therapies.",
            "signal expertise": "Benjamin is stating his experience and knowledge in the area of antibody development and synthetic biology."
        }
    },
    {
        "utterance": "Benjamin Bartelle: We know that this drug goes hits T cells specifically. Great, we're building a theragnostic that's going to find the T cells and report back to us that it's done a job in it. So we have there is a way of bypassing some of that initial safety testing if you do go with these um biologics or just antibodies that are already approved. So there there's some hope there and I think the as we get better and better at this, we may start building out something like a grass list, you know, it's like generally recognized as safe list. ",
        "annotations": {
            "propose new idea": "introducing a new approach to drug development by utilizing approved biologics or antibodies as a foundation for new therapies.",
            "develop idea": "elaborating on how using existing biologics or antibodies could streamline the development of new therapeutic approaches.",
            "supportive response": "expressing optimism about the potential of this approach to simplify safety testing and drug development."
        }
    },
    {
        "utterance": "mark sellmyer: Good points. ",
        "annotations": {
            "acknowledge contribution": "The speaker is acknowledging a previous point made by someone else.",
            "supportive response": "The speaker is expressing agreement or validation with the previous points made."
        }
    },
    {
        "utterance": "Dr. Anna Moore: But but I'm still wondering if, you know, wouldn't it be great if every single drug that you uh inject has somewhat some kind of an image image guided guidance image guiding properties. So you can monitor this drug. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new idea about the benefits of having image-guided properties in drugs for better monitoring.",
            "develop idea": "The speaker builds upon previous discussions about improving drug delivery and monitoring by suggesting a specific application of imaging technology."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Uh, without sacrificing, you know, many, many animals. And avoiding those costly studies that you have to pay for because you can actually do it yourself. ",
        "annotations": {
            "Identify gap": "The speaker recognizes the current reliance on sacrificing many animals and conducting costly studies as significant issues.",
            "Supportive response": "The speaker expresses a positive evaluation of image-guided therapies.",
            "Offer feedback": "The speaker suggests an alternative approach to improve the drug development process."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Because you can get quantitative data. ",
        "annotations": {
            "develop idea": "Dr. Anna Moore is expanding on the benefits of image-guided therapies, specifically highlighting the advantage of obtaining quantitative data."
        }
    },
    {
        "utterance": "Sixian You: So what I'm hearing is that uh, so for therapies, the major barrier is actually in biology is in in the therapies. ",
        "annotations": {
            "develop idea": "The speaker is reflecting on the discussion about the major barrier in therapies, which is a form of developing the idea.",
            "summarize conversation": "The speaker is summarizing what they've heard about the major barrier being in biology for therapies."
        }
    },
    {
        "utterance": "Sixian You: It's not image guiding technologies. But if we want to develop image guiding technologies, it will be helpful to develop something that can monitor these early changes induced by the drugs. ",
        "annotations": {
            "propose new idea": "The speaker suggests a new approach for developing image-guiding technologies by monitoring early changes induced by drugs.",
            "develop idea": "The utterance expands on the concept of improving drug development and image-guiding technologies by highlighting a specific need.",
            "clarify goal": "The speaker clarifies that a goal for image-guiding technologies is to monitor early drug-induced changes."
        }
    },
    {
        "utterance": "Sixian You: So either is the delivery of the. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Dr. Anna Moore: With companion diagnostics. ",
        "annotations": {
            "clarify goal": "The speaker clarifies the potential role of companion diagnostics in therapy development and monitoring, indicating a goal of integrating diagnostics with therapeutic interventions."
        }
    },
    {
        "utterance": "Sixian You: Companion diagnostics. ",
        "annotations": {
            "acknowledge contribution": "The speaker is acknowledging or mentioning companion diagnostics as a relevant concept."
        }
    },
    {
        "utterance": "Molly Bright: Can I weigh in on a completely different take on on I guess yeah. ",
        "annotations": {
            "encourage participation": "The speaker is inviting others to contribute their thoughts or ideas by asking if they can weigh in on a different take."
        }
    },
    {
        "utterance": "Molly Bright: So I think about it from the other end and I guess I'm surrounded by very long-term treatments and also ambiguous treatments. So there are so many therapeutics and drugs that we use in humans that may or may not work for someone, we don't know how to dose it and we don't have an imaging marker of what it's doing particularly in the brain. ",
        "annotations": {
            "identify gap": "Molly explicitly mentions gaps in current knowledge, specifically about dosing and imaging markers.",
            "develop idea": "Molly is expanding on her thoughts about the challenges with therapeutics and drugs."
        }
    },
    {
        "utterance": "Molly Bright: Um, so that's that's my domain would be the brain, that's unfortunately what I can focus on. But there are so many drugs that I think sit into this category and if you think of all of the mood disorders and anything to do with mental health, anything to do with long-term degeneration of neural function uh and and dementia. ",
        "annotations": {
            "develop idea": "The speaker is expanding on her thoughts about drugs related to her domain of expertise.",
            "signal expertise": "The speaker explicitly states her area of focus or expertise.",
            "identify gap": "The speaker highlights a gap in knowledge or treatment for certain conditions."
        }
    },
    {
        "utterance": "Molly Bright: We need a time scale of looking at. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Molly Bright: What a drug does and what happens in the absence of that drug in the face of huge human variability to evaluate if we're remotely close to getting after what we're after. ",
        "annotations": {
            "identify gap": "The speaker highlights the challenge of evaluating drug effects due to huge human variability.",
            "clarify goal": "The utterance aids in clarifying the objective of drug evaluation, which is to assess effectiveness in various human populations."
        }
    },
    {
        "utterance": "Molly Bright: And that is a huge cost. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance."
        }
    },
    {
        "utterance": "Molly Bright: Sorry, downer. ",
        "annotations": {
            "express humor": "Molly Bright is making a lighthearted comment about the potential negativity of her previous discussion, indicating humor."
        }
    },
    {
        "utterance": "mark sellmyer: Well, I don't know. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "mark sellmyer: Is hyperpolarized a way forwards to look at function in the brain using hyperpolarized substrates with MRI? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on the use of hyperpolarized substrates with MRI for assessing brain function."
        }
    },
    {
        "utterance": "Molly Bright: Is that really going to get at the. ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on a prior statement."
        }
    },
    {
        "utterance": "Molly Bright: The limitation of this scale of treatment efficacy? Yeah. ",
        "annotations": {
            "Supportive Response": "The speaker is expressing agreement and acknowledgment of the previous discussion about the limitations of treatment efficacy."
        }
    },
    {
        "utterance": "mark sellmyer: Right. So so efficacy as measured by some um, for psychiatric disease. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement or validation for a previous statement, particularly in the context of challenges related to psychiatric diseases."
        }
    },
    {
        "utterance": "mark sellmyer: Really hard to measure, well, harder to measure than let's say a tumor size, you know. ",
        "annotations": {
            "critical response": "The speaker is questioning the feasibility of measuring treatment efficacy in psychiatric diseases by comparing it to the relatively easier task of measuring tumor size."
        }
    },
    {
        "utterance": "Benjamin Bartelle: almost worse that we have the wrong. ",
        "annotations": {
            "Critical Response": "The speaker expresses a negative evaluation or concern about the current state of affairs, implying that having the wrong approach might be almost worse than another unspecified issue."
        }
    },
    {
        "utterance": "Benjamin Bartelle: metrics, right? Like Biogen Idec just spent a billion dollars on this drug that reduces Alzheimer's plaques and it worked in mice and it works in people. It reduces the Alzheimer's plaque, doesn't do anything else. You still have Alzheimer's, you just don't see the plaques as bad anymore. And so they're image guided biomar, their imaging biomarker was absolutely wrong and they were completely all in on it and they're still trying to get it to work. So so you can really get led astray with these things, yeah. ",
        "annotations": {
            "critical response": "The speaker is questioning and providing a negative evaluation of Biogen Idec's approach to drug development based on imaging biomarkers.",
            "offer feedback": "The speaker is providing insights on the potential pitfalls of relying solely on imaging biomarkers for assessing drug efficacy."
        }
    },
    {
        "utterance": "Molly Bright: Any anything positive to say in this direction to balance what I've done to the conversation? ",
        "annotations": {
            "ask question": "The speaker is requesting information or feedback from others."
        }
    },
    {
        "utterance": "Benjamin Bartelle: It's a world of opportunity. ",
        "annotations": {
            "supportive response": "Expressing a positive outlook and encouragement on the challenges and opportunities discussed."
        }
    },
    {
        "utterance": "Lisa Poulikakos: understanding. So maybe on Ben's point. So basically this drug reduced the plaques in Alzheimer's and in mice it also reduced symptoms but in humans it didn't reduce symptoms. Is that correct? ",
        "annotations": {
            "ask question": "The speaker is requesting confirmation or clarification on a previous point.",
            "acknowledge contribution": "The speaker references and builds upon a previous point made by Ben.",
            "summarize conversation": "The speaker summarizes a part of the conversation to ensure understanding."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah. That's Aducanumab is the story there. ",
        "annotations": {
            "develop idea": "The speaker is expanding on a previous idea by providing a specific example (Aducanumab).",
            "acknowledge contribution": "The speaker is acknowledging a previous point and adding an example, which can be seen as acknowledging a contribution."
        }
    },
    {
        "utterance": "Lisa Poulikakos: Okay, interesting. And does are there any ideas why or it's completely unknown? ",
        "annotations": {
            "ask question": "The speaker is requesting information about potential reasons or explanations for the discrepancy in drug effects between mice and humans."
        }
    },
    {
        "utterance": "Benjamin Bartelle: The the amyloid hypothesis um was you know super popular this gets back to Crystal's original point, which is uh people get hung up stuck on these mechanisms and they seem to be what you're after and in mice these amyloid plaques removal of the amyloid plaques was highly correlated with the um positive outcomes in these Alzheimer's models. We don't know if the Alzheimer's models are accurate. We don't know if Alzheimer's plaques that you see are anyway like related directly to Alzheimer's in humans. Uh human patients often have Alzheimer's plaques. They often have Alzheimer's plaques and no Alzheimer's. They sometimes have no plaques and Alzheimer's. So it was enough it was enough to go on where the animals model animal models worked. So it was worth pursuing because they were getting good data here and they could see their imaging biomarker in humans work. But it turned out or ",
        "annotations": {
            "develop idea": "The speaker is expanding on the amyloid hypothesis by providing examples and questioning its validity across species.",
            "ask question": "The speaker asks questions about the accuracy of Alzheimer's models and the relationship between amyloid plaques and Alzheimer's in humans.",
            "identify gap": "The speaker identifies a gap in understanding the relationship between amyloid plaques and Alzheimer's disease in humans versus mice.",
            "critical response": "The speaker provides a critique of the amyloid hypothesis and its application across species.",
            "offer feedback": "The speaker offers feedback on the amyloid hypothesis and its limitations."
        }
    },
    {
        "utterance": "Lisa Poulikakos: That's crazy. ",
        "annotations": {
            "critical response": "The speaker expresses astonishment and disbelief at the discrepancy between the drug's effects in mice versus humans."
        }
    },
    {
        "utterance": "Benjamin Bartelle: I mean the case is still they're still making their case. There's their other companies based on the same amyloid hypothesis still testing the same thing. There may be some condition where it works but as yet it it does not work. So ",
        "annotations": {
            "develop idea": "Benjamin Bartelle is expanding on the discussion about the amyloid hypothesis and its implications for Alzheimer's research.",
            "critical response": "He is providing a critical perspective on the current state of treatments based on the amyloid hypothesis, highlighting their limitations.",
            "identify gap": "Benjamin Bartelle points out a gap in current research, noting that while there may be some condition where the treatment works, it does not work for Alzheimer's."
        }
    },
    {
        "utterance": "Lisa Poulikakos: That's crazy. ",
        "annotations": {
            "critical response": "The speaker is expressing surprise or skepticism at the information provided by Benjamin Bartelle, questioning the logic or outcome of the drug's effects."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Where did they go wrong? Did they go wrong in dish where they saw these amyloid plaques and got completely locked in on it? Did they go wrong in their animal models? Is that actually relevant to mice where the plaques are important for mice and cured them? Or is there something else going on in humans where we're just not seeing that part? Like we're getting half of it. You have it's maybe it's necessary but not sufficient. We don't know any of that stuff yet just because the human work is so slow and the one molecular marker we spent so much time on, you know these great pet tracers for Alzheimer's plaques. ",
        "annotations": {
            "critical response": "The speaker is questioning and challenging the approach taken by another group regarding their research on Alzheimer's plaques.",
            "ask question": "The speaker is requesting information or clarification on where the research went wrong.",
            "identify gap": "The speaker explicitly mentions a lack of knowledge about the human aspects of Alzheimer's disease research."
        }
    },
    {
        "utterance": "Lisa Poulikakos: That's crazy. Why? Oh, that's yeah, amazing. ",
        "annotations": {
            "ask question": "The speaker requests information or clarification with 'Why?'",
            "supportive response": "The speaker expresses engagement and surprise."
        }
    },
    {
        "utterance": "Molly Bright: I I mean maybe one way to distill one of these issues is the time scale of knowing efficacy in humans is way too long. Um I don't know how like is there a way to work backwards? I I'm I'm not sure. Um but to to always go from small to big could mean that an entire direction is not wasted but mistargeted. ",
        "annotations": {
            "code name": "ask question",
            "explanation": "Molly explicitly asks if there's a way to work backwards in the research process."
        }
    },
    {
        "utterance": "Benjamin Bartelle: What if the mechanism for Alzheimer's the disease progression in Alzheimer's in human beings has never actually been seen because you can't recapitulate it in a dish and you can't recapitulate it in a mouse. I don't I don't know but what if that's true then everything we're doing is wrong in Alzheimer's. And as yet there are no there are no root cause treatments for any neurodegeneration and maybe it's because we're not seeing it because we're not looking in the right place. It's possible. A world of opportunity. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new perspective on Alzheimer's research, questioning current models.",
            "develop idea": "The speaker expands on the implications of this new perspective.",
            "critical response": "The speaker challenges current approaches to Alzheimer's research."
        }
    },
    {
        "utterance": "Molly Bright: We'll always have a job. Um but it's ",
        "annotations": {
            "Express humor": "The speaker makes a humorous comment about always having a job, implying that there will be ongoing challenges or work in their field."
        }
    },
    {
        "utterance": "Mark Sellmyer: Molly, I think your question is good about time scales, right? And the the very last question of our group 2.3 topic is can we integrate imaging across time to see the impact of a previous dosing over weeks to months or can you integrate, you know, biologic processes over time to capture something that might be a longer um longer in the making and longer in the resolution. It's tough. ",
        "annotations": {
            "develop idea": "The speaker is expanding on an existing idea about integrating imaging across time to see the impact of previous dosing.",
            "ask question": "The speaker is requesting information on how to integrate imaging across time."
        }
    },
    {
        "utterance": "Crystal Rogers: There are people doing primate research to do exactly this, right? So there was a whole session that the ORIP had about the importance of primate research, which again still isn't the same, but at least it scales up to um to us as primates. But I think that is the same it's the same thing again, right? Super expensive, very time consuming, still not exactly the same physiology and there's no guarantee that it will directly translate to humans. So so I don't know what I said. I don't think I added anything, but I just wanted to bring that up again that it we do have a way to test um it's just it's not efficient and it's super hard. ",
        "annotations": {
            "develop idea": "The speaker elaborates on the idea of using primate research, discussing its potential and limitations.",
            "identify gap": "The speaker highlights the limitations and challenges of primate research, including cost, time consumption, and physiological differences.",
            "acknowledge contribution": "The speaker downplays their contribution to the discussion."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Millions of dollars going into marmosets for this exact reason of like maybe if mice don't tell us, maybe marmosets will. Millions being invested. Every every big neuroscience lab in America is is putting together their marmoset program in the hopes that it's going to be relevant. ",
        "annotations": {
            "develop idea": "Benjamin Bartelle is expanding on the concept of using marmosets in research, suggesting it as a potentially more relevant model than mice for understanding human diseases.",
            "critical response": "He is questioning the effectiveness of mice models by implying that marmosets, despite their higher cost and complexity, might provide more relevant insights, which can be seen as a critique of current research methods."
        }
    },
    {
        "utterance": "Mark Sellmyer: Right. ",
        "annotations": {
            "acknowledge contribution": "The speaker is acknowledging a prior statement.",
            "supportive response": "The speaker is expressing agreement with a previous statement."
        }
    },
    {
        "utterance": "Sixian You: Do we see a future in genetic reporters in human beings? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on the potential future role of genetic reporters in human beings."
        }
    },
    {
        "utterance": "Benjamin Bartelle: I do. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement or validation for the potential of genetic reporters in human beings."
        }
    },
    {
        "utterance": "Mark Sellmyer: Yeah. It seemed impossible 10 years ago, but now with I mean everyone's everyone's getting into a cell based therapy and what do you how are you going to track those things? ",
        "annotations": {
            "develop idea": "The speaker discusses the progression and challenges of cell-based therapies, developing the idea of their application and tracking.",
            "ask question": "The speaker asks a question about how to track cell-based therapies.",
            "encourage participation": "The speaker invites discussion by posing a question about tracking cell-based therapies."
        }
    },
    {
        "utterance": "Dylan Burnette: But what I really don't think about as scientists often to uh is is is scary as hell. You don't have the background when someone says I'm going to put this cell in you is not your cell or it's your cell and I changed it a little bit. That is where we are that's where we're starting from with most of the general public because we're bought in because we know details. And communication is very difficult. We don't even pay science communicators very much. They they barely even exist to be honest. They're all freelancers out there. Um and so I I I I I'm afraid that that's going to fall on us. So so when Crystal was talking I was like, Yeah. ",
        "annotations": {
            "identify gap": "The speaker identifies a gap in how the public perceives scientific advancements and the challenges in communication.",
            "critical response": "The speaker is expressing a negative evaluation of the current state of public perception and communication in science."
        }
    },
    {
        "utterance": "Mark Sellmyer: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Sixian You: Do we see a future in genetic reporters in human beings? ",
        "annotations": {
            "ask question": "The speaker is requesting information or thoughts on the future of genetic reporters in human beings."
        }
    },
    {
        "utterance": "Benjamin Bartelle: I do. ",
        "annotations": {
            "supportive response": "The speaker expresses agreement with the idea of a future in genetic reporters in human beings, providing a positive evaluation without adding new content."
        }
    },
    {
        "utterance": "Mark Sellmyer: It's like that. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah. Let's do it. Let's go. ",
        "annotations": {
            "supportive response": "The utterance expresses agreement and enthusiasm for a previous idea or suggestion."
        }
    },
    {
        "utterance": "Crystal Rogers: It's a great idea, but that requires a massive effort in science communication. And so if people won't take a vaccine to save their lives, I don't know that anybody would want to have a reporter uh inside of them. So I think we have these issues here. We are all for it. Like inject me, go for it, but um so there have to there has to be a a front of us being the scientists and the clinicians and also explaining how important and innocuous some of these things can be. They can be helpful. They can be, you know, therapeutic. They can also be um diagnostic but or theragnostics, right? That's the the term. But ",
        "annotations": {
            "critical response": "The speaker questions the feasibility of implementing genetic reporters due to public acceptance issues.",
            "encourage participation": "The speaker emphasizes the need for scientists and clinicians to take a front role in explaining the importance and safety of these technologies."
        }
    },
    {
        "utterance": "Dylan Burnette: It's like that. It's yeah. ",
        "annotations": {
            "supportive response": "The utterance expresses agreement or validation for a previous statement."
        }
    },
    {
        "utterance": "Mark Sellmyer: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Dylan Burnette: I I I ran into this yesterday. I was trying to I was trying to consent a patient to image their bacteria. And the question is is is your test going to help me in any way? Yeah. And the response is it can't because it's investigational as an imaging and diagnostic it will not change your management at all. The difference for the therapy folks is they're like we don't know. We're going to see it might help you. And so that's a huge like just big difference between therapeutic intervention trials and like diagnostic like, you know, approaches. Yeah. But but what I really don't think about as scientists often to uh is is is scary as hell. You don't have the background when someone says I'm going to put this cell in you is not your cell or it's your cell and I changed it a little bit. That is where we are that's where we're starting from with most of the general public because we're bought in because we know details. And communication is very difficult. We don't even pay science communicators very much. They they barely even exist to be honest. They're all freelancers out there. Um and so I I I I I'm afraid that that's going to fall on us. ",
        "annotations": {
            "signal expertise": "The speaker shares his experience and insights gained from his professional activities, implying his expertise in the field.",
            "identify gap": "The speaker identifies a gap in communication and understanding between scientists and the general public."
        }
    },
    {
        "utterance": "Dylan Burnette: and that they shouldn't be, but maybe they should, right? ",
        "annotations": {
            "supportive response": "The speaker is expressing a supportive stance towards the importance of science communication or similar entities, indicating agreement with the previous discussion.",
            "ask question": "The speaker ends with a rhetorical question 'right?', seeking agreement."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, well, there's another approach, uh, you know, when you're talking about cell-based therapies and you need to track those cells, you don't necessarily have to have a permanent, you know, imaging reporter in your body, you could just label cells before you inject them with some kind of a label that is visible for the scanner, whether it's magnetic label, you know, I'm a nanoparticle person, so obviously, um, that's what what comes to mind, but also what's biodegradable and gets, you know, gets outside your body at some point. So that doesn't seem so scary, does it? ",
        "annotations": {
            "develop idea": "Dr. Moore is expanding on the concept of tracking cells in cell-based therapies by suggesting the use of temporary labels.",
            "signal expertise": "Dr. Moore mentions being a 'nanoparticle person', indicating her expertise in nanoparticles."
        }
    },
    {
        "utterance": "Benjamin Bartelle: longitudinally, I've I've had very little success with that. If you're trying to look at something over months, the chances you're going to find that nanoparticle laden T cell or that nanoparticle laden, you know, stem cell and have it persist over the months you need to follow the disease progression or therapy progression. Like we've been trying that for a long time since before I started grad school and it's just without having that genetic persistence, it hasn't worked. ",
        "annotations": {
            "develop idea": "He is expanding on the challenges of tracking cells over time.",
            "identify gap": "He identifies a gap in their approach, the need for genetic persistence.",
            "offer feedback": "He is providing feedback based on his experience."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, I'm just saying like, you know, that's that's one problem with we can talk we can actually talk about that because our experience is that you could follow them for quite some time providing that cells do not divide because if they divide, then they dilute the material obviously. And and there has to be complementary methods to basically see the effect of your therapy. So you cannot kill, you know, many bunnies with one I I hate even saying that. That doesn't sound good. ",
        "annotations": {
            "develop idea": "Dr. Anna Moore is expanding on the idea of tracking cells over time and conditions for doing so.",
            "express humor": "The phrase about not wanting to kill many bunnies with one approach is a humorous way to express a concern about efficiency in research."
        }
    },
    {
        "utterance": "Benjamin Bartelle: I've never heard this analogy, so. ",
        "annotations": {
            "identify gap": "The speaker explicitly states a lack of knowledge about a previously mentioned analogy."
        }
    },
    {
        "utterance": "Dr. Anna Moore: No. So, um, okay, so we got a, we got a warning, uh, T minus 15 minutes till the end of our. ",
        "annotations": {
            "process management": "Dr. Anna Moore is managing the meeting flow by informing the group that they have 15 minutes left until the end of the meeting."
        }
    },
    {
        "utterance": "Dr. Anna Moore: So basically what I was trying to say, I think you need more than one modality and more than one imaging, uh, you know, to even monitor one process. It seems like, you know, it has to be several different approaches just to make sure that your cells are injected, that they get where they have to go, uh, how much get lost on the way, whether they're doing what they're supposed to do, uh, and whether there's any improvement. So like right there it's like 1.5, like four, four different things that you need to monitor and you need four different ways to do that. I don't believe that there is like this universal contrast agent that can, you know, you can inject it and it's going to monitor everything. It doesn't exist. So anyway, so, um, like I said, we have, uh, 14 minutes now. ",
        "annotations": {
            "develop idea": "expanding on the idea that monitoring cell-based therapies requires multiple approaches",
            "offer feedback": "sharing her perspective on the necessity of multiple modalities for effective monitoring"
        }
    },
    {
        "utterance": "Sixian You: I just put down whatever I'm hearing. So I think for the next 10 minutes, can we just uh, uh, each say or just uh, input like what is the most exciting idea you heard in this meeting or you you are summarizing and we put three major ideas in in the chat instead of uh, everything. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new suggestion for summarizing the meeting discussion.",
            "encourage participation": "The speaker invites everyone to contribute their ideas.",
            "process management": "The speaker is managing the meeting flow by suggesting a method for discussion summary."
        }
    },
    {
        "utterance": "Sixian You: So, so summarizing, I think um, Anna said it pretty well, so it has to be a combination of multimodal approaches uh, for these four different processes. I hear the delivery process and then the efficacy process. The other two I didn't catch it. So. ",
        "annotations": {
            "develop idea": "The speaker is expanding on Anna's previous idea about needing a combination of multimodal approaches.",
            "summarize conversation": "The speaker is summarizing the discussion, specifically mentioning the need for multimodal approaches for four different processes.",
            "ask question": "The speaker is indirectly asking for clarification on the two processes they didn't catch.",
            "process management": "The speaker is managing the discussion by summarizing and seeking clarity."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, the other thing is delivery process and then, uh, you want to be able to monitor what you delivered, if it's still there, if it's still intact, if it's still functioning. ",
        "annotations": {
            "develop idea": "The utterance expands on the idea of monitoring therapies by specifying aspects to monitor (delivery process, if it's still there, intact, functioning).",
            "identify gap": "The utterance implies a gap in current capabilities - the ability to monitor therapies effectively.",
            "clarify goal": "The utterance helps clarify the goal of monitoring therapies."
        }
    },
    {
        "utterance": "Dr. Anna Moore: You know, like say the cells, right? The cell therapy, uh, are they still functioning? Are they still like for example with islet transplantation, you put islets in the human body and 60% of them dead two weeks after transplantation. ",
        "annotations": {
            "Develop idea": "The speaker is elaborating on the challenges of cell therapy, specifically regarding the functionality of cells post-transplantation.",
            "Identify gap": "The speaker is pointing out a gap in current capabilities, specifically that 60% of islets die after transplantation, indicating a need for better methods to monitor or improve cell survival."
        }
    },
    {
        "utterance": "Dr. Anna Moore: And you don't know where they went, you don't know what they're doing, you don't know if they're producing insulin, you're blind completely. And each, uh, islet batch comes from a donor who's obviously deceased. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the challenges of cell therapy, specifically the inability to track cells post-transplantation.",
            "signal expertise": "Dr. Anna Moore is explicitly stating her knowledge and experience in the field, particularly concerning cell tracking and transplantation.",
            "identify gap": "The utterance explicitly recognizes a lack of knowledge about the behavior and fate of transplanted cells."
        }
    },
    {
        "utterance": "Dr. Anna Moore: So it's just an example. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Sixian You: Mhm. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Sixian You: One idea that I think is super exciting is this idea of long-term genetic reporters. It is high risk, it is very controversial, but um, but for auto imaging they provide really good contrast and they they're they're almost forever if they don't get injected, ejected out of the body. ",
        "annotations": {
            "propose new idea": "The speaker introduces the idea of long-term genetic reporters as an exciting concept worth considering.",
            "develop idea": "The speaker elaborates on the potential benefits and challenges of long-term genetic reporters, such as providing good contrast and being high-risk and controversial."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Genetic reporter, I'm all for it. I have one. Anyone wants it. ",
        "annotations": {
            "signal expertise": "Benjamin Bartelle implies he has experience or knowledge about genetic reporters by stating he has one.",
            "supportive response": "Benjamin Bartelle expresses agreement or support for genetic reporters."
        }
    },
    {
        "utterance": "Benjamin Bartelle: We bring up theranostic a lot. We've said that a number of times. Um, and it's the great thing to say, um, but what exactly is a theranostic when we go through it and it neither needs to be um, some nanotechnology, some macromolecular complex that is detectable and sensitive to a specific readout or it needs to be uh an engineered cell that uh is detectable and then can change its its signal or shape. You need to have that level of complexity to have a theranostic. ",
        "annotations": {
            "Develop idea": "The speaker is expanding on the concept of theranostics, explaining what it can involve.",
            "Ask question": "The speaker is asking a question about the nature of theranostics."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Oh, it has to be for the right mechanism. ",
        "annotations": {
            "develop idea": "The speaker is discussing a necessary condition for theranostics to be effective, building on existing ideas.",
            "offer feedback": "The statement implies that a theranostic approach must be suited to the right mechanism, which can be seen as feedback for improving such approaches."
        }
    },
    {
        "utterance": "Benjamin Bartelle: I think that was the thing. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Benjamin Bartelle: Okay. ",
        "annotations": {
            "None": "The utterance is a brief acknowledgment or agreement, and no specific code from the codebook applies."
        }
    },
    {
        "utterance": "Dylan Burnette: But we haven't really talked too much about toxicity and the ability to actually detect uh tissue that is dying either through necrosis or apoptosis or some either programmed or not programmed cell death. It's something that is would be quite useful I think if you're putting drugs into people and then you want to drugs where they go where they go, but if they're causing damage along the way or when they get concentrated at the side of of where they're supposed to be at, it's hard to tell. Um, and I know in in in neurobiology if you actually saw the neurons dying that wouldn't be bad. ",
        "annotations": {
            "identify gap": "The speaker identifies a gap in current capabilities regarding detecting tissue that is dying due to drug toxicity.",
            "develop idea": "The speaker is building upon previous discussions about drug delivery and imaging by highlighting another critical aspect - toxicity and detecting cell death.",
            "offer feedback": "The speaker provides feedback on the importance of addressing the detection of tissue damage."
        }
    },
    {
        "utterance": "Benjamin Bartelle: So you're saying cell death as a target for our imaging and theranostic then. Like understanding that. Yeah, so if you had a read out to to to actually monitor uh the the target tissues uh actual death or not because sometimes in the case of cancer you want to kill these things, but sometimes you don't want to kill it. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the concept of using imaging and theranostics to monitor cell death.",
            "ask question": "The speaker is requesting information about the capability to monitor cell death.",
            "offer feedback": "The speaker is providing feedback on the concept by highlighting its importance in different scenarios."
        }
    },
    {
        "utterance": "Dylan Burnette: So so it could be both targeted and just a general read out of toxicity because sometimes you don't want your cells to die. Um, as a matter of fact, I don't want more of my cells to die in general. ",
        "annotations": {
            "develop idea": "The speaker is building upon previous conversations about imaging and cell death, suggesting a way to approach the topic.",
            "offer feedback": "The speaker is providing a perspective on how to approach the issue of cell death in treatment or experimentation.",
            "identify gap": "The speaker implies a gap in current capabilities regarding the monitoring of cell death."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, a long time ago there was an an an ex in five probes developed, I would say 20 years ago to monitor tumor response to therapy. ",
        "annotations": {
            "summarize conversation": "The speaker references a past development to monitor tumor response to therapy, bringing it up as part of the conversation history."
        }
    },
    {
        "utterance": "Benjamin Bartelle: just like, oh, everything's ferroptosis, right? ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance as it does not explicitly introduce a new idea, develop an existing idea, ask a question, signal expertise, identify a gap, acknowledge a contribution, offer feedback, summarize, express humor in a conventional sense, encourage participation, manage process, assign a task, clarify a goal, or confirm a decision in a straightforward manner."
        }
    },
    {
        "utterance": "Dylan Burnette: Um, but uh, but so it's it's probably impossible to have one particular marker to pull off, you know, actually knowing what kind of of cell death, but it would be nice to know if cells are alive or not inside of of a biotic. ",
        "annotations": {
            "identify gap": "The speaker highlights the difficulty in having one particular marker for cell death.",
            "develop idea": "The speaker expands on the idea of alternatives to specific cell death markers.",
            "offer feedback": "The speaker provides feedback on the challenges of cell death markers and suggests an alternative focus."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. So, um, so let's see. So, um, Sision, do you do you feel comfortable talking about those things? ",
        "annotations": {
            "encourage participation": "Dr. Anna Moore invites Sision to contribute to the conversation by asking if they feel comfortable discussing certain topics."
        }
    },
    {
        "utterance": "Sixian You: Actually, uh, yeah, I I think I can only catch understand like 50% of these conversations. I think my biology is probably high school level, so. ",
        "annotations": {
            "identify gap": "Sixian You explicitly states a lack of knowledge in biology, identifying a gap in their understanding."
        }
    },
    {
        "utterance": "Benjamin Bartelle: That's pretty good though. 50%'s pretty good. ",
        "annotations": {
            "acknowledge contribution": "Benjamin Bartelle is acknowledging Sixian You's contribution by responding to their comment.",
            "supportive response": "Benjamin Bartelle is providing a positive and supportive response to Sixian You's self-assessment."
        }
    },
    {
        "utterance": "Sixian You: So if anybody wants to take over, I'm totally comfortable because I think the best thing is that we present the best ideas in the room. Um, yeah. ",
        "annotations": {
            "encourage participation": "The speaker invites others to contribute or take over, showing willingness to step back and let others lead or participate."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Nah, you got this. Come on. ",
        "annotations": {
            "Supportive response": "Benjamin is offering encouragement to Sixian.",
            "Encourage participation": "Benjamin is encouraging Sixian to participate or take over."
        }
    },
    {
        "utterance": "Sixian You: Okay. So. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Benjamin Bartelle: Do we we have our our barriers, our targets, our agents, our approaches. This is all getting really well organized, so I. ",
        "annotations": {
            "process management": "Benjamin Bartelle is managing the discussion flow by checking if they have covered all necessary points (barriers, targets, agents, approaches) and commenting on the organization of their discussion."
        }
    },
    {
        "utterance": "Sixian You: Oh. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Benjamin Bartelle: I think it's really shaping up. ",
        "annotations": {
            "supportive response": "The speaker expresses a positive sentiment towards the progress or organization of the discussion."
        }
    },
    {
        "utterance": "Sixian You: Okay. So, uh, I guess to start, we can kind of present to the room like what are the barriers? Uh, and the barriers of course, disparity between the models and uh, the lack of understanding, uh, and the lack of tools to um, to validate toxicity and efficacy uh, in the short timeline. ",
        "annotations": {
            "identify gap": "The speaker explicitly mentions specific gaps or barriers (disparity between models, lack of understanding, lack of tools).",
            "process management": "The speaker is suggesting a way to organize the discussion by presenting the barriers to the room."
        }
    },
    {
        "utterance": "Sixian You: And then to address that, we could first we could um, focus more efforts on different targets, uh, list at this and then contrast agency is another effort and then uh, in the end it will be a combination multi model approaches of all this. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by suggesting focusing on different targets and considering contrast agents as part of a multi-model approach.",
            "offer feedback": "The speaker provides specific suggestions for addressing the issue at hand."
        }
    },
    {
        "utterance": "Sixian You: Where does imaging come in? The multimodal approaches in the contrast agents? ",
        "annotations": {
            "ask question": "The speaker is requesting information about the role of imaging in the context of multimodal approaches and contrast agents."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah. I mean that's what we mean by multimodal, multimodal imaging. ",
        "annotations": {
            "develop idea": "Benjamin Bartelle is expanding on the concept of multimodal imaging by providing further clarification on what it means."
        }
    },
    {
        "utterance": "Crystal Rogers: Well, and also in the technological development, right, to be able to actually see the efficacy of these things live in an organism. Someday. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea of needing technological advancements to observe efficacy in organisms.",
            "identify gap": "The speaker implies a gap in current technology, specifically in being able to see the efficacy of things live in an organism.",
            "clarify goal": "The speaker is highlighting the importance of technological development for the goal of observing efficacy in organisms."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Is is is multimodal approaches a subset of technological development then? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on whether multimodal approaches are a subset of technological development."
        }
    },
    {
        "utterance": "Crystal Rogers: It is. Yes. ",
        "annotations": {
            "acknowledge contribution": "The speaker is acknowledging a point made by another group member."
        }
    },
    {
        "utterance": "Sixian You: Yeah. Uh-huh. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Benjamin Bartelle: I guess all this stuff then. These things are all like uh development of 3D culture, visualization of delivery. That's all tech development that we're all tracking. ",
        "annotations": {
            "summarize conversation": "The speaker is summarizing and connecting different ideas discussed in the meeting, specifically mentioning development of 3D culture and visualization of delivery as part of tech development."
        }
    },
    {
        "utterance": "Sixian You: So, I can delete this and uh, put multimodal approaches here. ",
        "annotations": {
            "process management": "The speaker is suggesting an action to manage the content of a presentation or document during the meeting."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Crystal Rogers: I think the 3D cell culture stuff is also part of technological development, bioprinting, etc. ",
        "annotations": {
            "develop idea": "Crystal Rogers is expanding on existing ideas by including 3D cell culture and bioprinting as part of technological development."
        }
    },
    {
        "utterance": "Sixian You: Uh, that is also, okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Sixian You: I think we talked about this before. Yeah, particle, nanoparticle is already in the contrast agents. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges a previous point made about nanoparticles being included in contrast agents."
        }
    },
    {
        "utterance": "Benjamin Bartelle: You can make the the font smaller too if it doesn't fit. That's uh that's the easy one. ",
        "annotations": {
            "Express humor": "The speaker makes a lighthearted comment about the ease of solving a formatting issue, indicating humor."
        }
    },
    {
        "utterance": "Morteza Mahmoudi: I also want to add the concept of like live contrast agents, like what happens with magnetotactic bacteria because like the dilution of the like the contrast agent is a big problem in the like the cell proliferation. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new concept of live contrast agents and mentions magnetotactic bacteria as an example.",
            "develop idea": "The speaker elaborates on the concept of live contrast agents by discussing the issue of dilution in cell proliferation."
        }
    },
    {
        "utterance": "Benjamin Bartelle: That's inherent in genetic reporters, right? That's what we mean when we say a live contrast agent. ",
        "annotations": {
            "develop idea": "The speaker is expanding on or clarifying an existing idea about genetic reporters and live contrast agents."
        }
    },
    {
        "utterance": "Morteza Mahmoudi: So the live contrast like there are papers coming out showing basically that magnetotactic bacteria can be used for like even increasing the like uh imaging uh sensitivity and capacity at the side of like for cell therapy applications, they they at least they showed promising results. So maybe adding. ",
        "annotations": {
            "propose new idea": "The speaker introduces the idea of using magnetotactic bacteria to increase imaging sensitivity and capacity in cell therapy applications.",
            "develop idea": "The speaker builds upon existing research by suggesting a potential application for magnetotactic bacteria."
        }
    },
    {
        "utterance": "Benjamin Bartelle: That's inherent in genetic reporters, right? That's what we mean when we say a live contrast agent. It's a a live reporter. I mean, I I agree. I agree with you completely. ",
        "annotations": {
            "supportive response": "Expressing agreement with Morteza Mahmoudi's statement about live contrast agents being inherent in genetic reporters."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay, we have uh probably one or a little bit over one minute left. So I just wanted to say that uh I I think it was fun. I think you know, I think we discussed a lot of different questions because the topic is so broad. And um if you guys you know, if you guys want to talk more about it, you know, my email is there. Uh you can email me or you can email each other. Please, um and uh hopefully we'll get this going and uh I'm looking forward to forming proposals from you guys. Just think what what you want to do. Um, you have complimentary expertise. Um, so we have a clinical person here. That's unique. So grab his expertise before it's too late. ",
        "annotations": {
            "Supportive response": "Dr. Moore expresses positive sentiments about the discussion and encourages further communication.",
            "Summarize conversation": "Dr. Moore mentions that they discussed a lot of different questions due to the broad topic.",
            "Encourage participation": "Dr. Moore invites others to email her or each other and encourages forming proposals.",
            "Process management": "Dr. Moore manages the meeting flow, noting the time and suggesting next steps.",
            "Signal expertise": "Dr. Moore mentions the presence of a clinical person and suggests utilizing their expertise."
        }
    },
    {
        "utterance": "Lisa Poulikakos: Thanks everyone. I feel like I learned a lot as a physics engineering person and I really appreciated the discussion. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement and appreciation for the discussion, showing a positive evaluation of the conversation."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Good. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Dr. Anna Moore: Me too. ",
        "annotations": {
            "supportive response": "Dr. Anna Moore is expressing agreement with Lisa Poulikakos's sentiment, indicating she also learned a lot and appreciated the discussion."
        }
    },
    {
        "utterance": "Sixian You: Yeah, I learned all the all the dark size and potentially price size of therapy. What I learned again is biology is so hard and medicine is so hard. ",
        "annotations": {
            "None": "The utterance is a personal reflection on the complexity of biology and medicine, not explicitly fitting into any other provided code category."
        }
    },
    {
        "utterance": "Lisa Poulikakos: I really really liked what Crystal said about the communication being key as we do push forward with anything shiny and new. ",
        "annotations": {
            "acknowledge contribution": "The speaker verbally recognizes another group member's input.",
            "supportive response": "The speaker is expressing agreement and positive evaluation for another group member's contribution."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, I totally agree. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement with a prior statement, showing support and validation for the contribution made."
        }
    },
    {
        "utterance": "Dylan Burnette: And I liked what Molly said about the difficulty with integrating over time scales and and having tractable metrics for many of the different diseases. ",
        "annotations": {
            "acknowledge contribution": "Dylan Burnette acknowledges Molly Bright's previous contribution about the difficulty with integrating over time scales and having tractable metrics for diseases.",
            "supportive response": "Dylan Burnette expresses agreement and validation for Molly Bright's comment, showing a supportive response to her idea."
        }
    }
]